Company
Normunity
We are developing novel anti-cancer therapies that work at the interface of the immune system and the tumor to target mechanisms that impact tumor growth and circumvent immune surveillance and tumor clearance.
Also known as Normunity Inc
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- Normunity Inc
- normunity.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 29 September 2026
About
We are developing novel anti-cancer therapies that work at the interface of the immune system and the tumor to target mechanisms that impact tumor growth and circumvent immune surveillance and tumor clearance.
Funding snapshot
- Total raised
- $140MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series B, $75M2025-01-13
Funding rounds
- Series B
- $75M2025-01-13, Company stated
- Series A
- $65M2022-10-25, Company stated
Products
- Other
- NRM-823
Loading relationship preview